NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
06 févr. 2024 08h00 HE
|
NightHawk Biosciences
DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK; SCPX), an integrated contract development and manufacturing organization (CDMO),...
NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer
01 févr. 2024 08h00 HE
|
NightHawk Biosciences
DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
30 janv. 2024 08h00 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
25 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
16 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
08 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK; NHWK), an integrated contract development and manufacturing organization (CDMO), today announced that it...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
03 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
21 déc. 2023 08h30 HE
|
NightHawk Biosciences
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as...
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
18 déc. 2023 08h30 HE
|
NightHawk Biosciences
Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this...
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
12 déc. 2023 08h30 HE
|
NightHawk Biosciences
Over $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million...